Jérôme Le Pavec
Le Pavec, Jérôme 1974-
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
VIAF ID: 208969245 (Personal)
Permalink: http://viaf.org/viaf/208969245
Preferred Forms
-
100 0 _
‡a
Jérôme Le Pavec
-
100 1 _
‡a
Le Pavec, Jérôme,
‡d
1974-
-
100 1 _
‡a
Le Pavec, Jérôme
‡d
1974-
4xx's: Alternate Name Forms (2)
Works
| Title | Sources |
|---|---|
| Allergic broncho-pulmonary aspergillosis following treatment with an anti-programmed cell death protein 1 monoclonal antibody therapy. |
|
| Alveolar Septal Widening as an "Alert" Signal to Look Into Lung Antibody-mediated Rejection: A Multicenter Pilot Study |
|
| artikull shkencor i botuar në vitin 2023 |
|
| Caractéristiques et survie des patients transplantés pulmonaires ou cardio- pulmonaires pour une hypertension pulmonaire précapillaire : étude observationnelle du registre français de l'hypertension pulmonaire |
|
| Central versus peripheral cannulation of extracorporeal membrane oxygenation support during double lung transplant for pulmonary hypertension. |
|
| Circovirus Hepatitis Infection in Heart-Lung Transplant Patient, France |
|
| Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis. |
|
| COLT : 10 ans de recherche en transplantation pulmonaire, résultats et perspectives |
|
| [Consortium for detection and management of lung damage induced by bleomycin]. |
|
| Current management approaches to portopulmonary hypertension. |
|
| Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. |
|
| Effets des immunosuppresseurs et des microparticules membranaires sur la transition épithélio-mésenchymateuse des cellules épithéliales bronchiques en culture 2D et 3D : intérêt en transplantation pulmonaire |
|
| Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension |
|
| Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer |
|
| Heart-lung transplantation: current indications, prognosis and specific considerations |
|
| Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. |
|
| Hypertension artérielle pulmonaire et sclérodermie systémique : les pièges |
|
| Hypertension portopulmonaire : aspects cliniques et biologiques |
|
| Impact of High-Priority Allocation on Lung and Heart-Lung Transplantation for Pulmonary Hypertension. |
|
| Life-threatening Hughes-Stovin syndrome: The Yin and Yang of anticoagulation therapy. |
|
| Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil |
|
| Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group |
|
| Natural History over 8 Years of Pulmonary Vascular Disease in a Patient Carrying Biallelic EIF2AK4 Mutations |
|
| De-novo donor-specific anti-HLA antibodies 30 days after lung transplantation are associated with a worse outcome. |
|
| Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease |
|
| Outcomes of hospitalisation for right heart failure in pulmonary arterial hypertension. |
|
| Perspectives on Scedosporium species and Lomentospora prolificans in lung transplantation: Results of an international practice survey from ESCMID fungal infection study group and study group for infections in compromised hosts, and European Confede |
|
| Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension |
|
| [Pulmonary arterial hypertension associated with common diseases: connective-tissue diseases, HIV infection and portal hypertension] |
|
| Pulmonary Hypertension Associated with Myeloproliferative Disorders: A Retrospective Study of Ten Cases |
|
| Pulmonary nodules and immunotherapy: disease progression or toxicity of anti-PD1/anti-PDL1 checkpoint inhibitors? |
|
| Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. |
|
| Role of C1q-binding anti-HLA antibodies as a predictor of lung allograft outcome |
|
| Scleroderma Lung Disease |
|
| Severe hematologic complications after lung transplantation in patients with telomerase complex mutations |
|
